Published at Forbes by Dara-Abasi Ita, on May 1st, 2026

Forbes reads our zero-shot redesign of cetuximab, completed in 8 hours from a single prompt with 2.1× the binding affinity of the originator, as a signal of where biologic drug development is heading.

The article asks what happens to the $10B pharma royalty market, to biotech credit, and to lifecycle strategy when our generative AI platform ConvergeAB can collapse the design step into a single prompt. It interviews investors, weighs counterpoints, and makes a serious case for a structural shift in how new biologics are made.

Read the article on Forbes